A2-Iso5-2DC18

A2-Iso5-2DC18 is a dihydroimidazole-linked lipid, served as potent mRNA delivery vehicle. A2-Iso5-2DC18 can be used for antitumor research, including B16F10 melanoma.[1].

Research Areas >> Cancer

Signaling Pathways >> Others >> Others

A2-Iso5-2DC18, loaded with mLuc or Cre-recombinase mRNA LNPs (mCre), (0.1 mg/kg and 0.5 mg/kg; s.c.; once a week, for 2 weeks) transfects central antigen presenting cells (APCs) in A14/Cre mRNA mouse model[1]. A2-Iso5-2DC18 loaded with OVA mRNA (mOVA) vaccine, (15 μg mOVA per mouse; s.c.; twice dose, once every 5 d) induces a significantly high antigen-specific cytotoxic T lymphocyte (CTL) response, in parallel with robust IFN-ɤ secretion in B16F10 mouse melanoma model[1]. Animal Model: A14/Cre mRNA mouse model (female B6 mice)[1] Dosage: Loaded with Cre-recombinase mRNA LNPs (mCre); 0.1 mg/kg and 0.5 mg/kg Administration: Subcutaneous injection; 3 weeks Result: Induced protein expression in the local injection site and the draining lymph nodes and transfected central antigen presenting cells (APCs) including macrophages/monocytes (CD11b+) and dendritic cells (CD11c+) in mice. Animal Model: Ovalbumin (OVA)-expressing B16F10 mouse melanoma model[1] Dosage: Loaded with OVA mRNA (mOVA) vaccine; 15 μg mOVA per mouse Administration: Subcutaneous injection; once per week for the first two weeks; 3 weeks continuous observation Result: Significantly decreased tumor volume of B16-OVA melanoma and improved overall survival in mice. Increased the number of systemic and tumor-infiltrating antigen-specific T cells dramatically (20–30-fold).